USE OF THE EXPRESSION OF SPECIFIC GENES FOR THE PROGNOSIS OF PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER

摘要

The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).